Business Context and Reporting Period
Company: Owens & Minor, Inc. (Note: Input metadata referenced "Accendra Health Inc," but the filing text is for Owens & Minor, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2008
Business Overview: A leading national distributor of medical and surgical supplies to the acute-care market and a healthcare supply-chain management company. The company distributes over 220,000 products to approximately 4,500 healthcare providers from 55 distribution centers. Primary customers include acute-care hospitals, often represented by Group Purchasing Organizations (GPOs) such as Novation, Premier, and Broadlane.
Key Financial Metrics (Year Ended Dec 31, 2008)
| Metric | 2008 | 2007 |
|---|---|---|
| Revenue | $7,243.2 million | $6,694.6 million |
| Net Income | $93.3 million | $72.7 million |
| Income from Continuing Operations | $101.3 million | $71.4 million |
| Diluted EPS (Net Income) | $2.25 | $1.79 |
| Gross Margin % | 9.90% | 9.71% |
| Operating Earnings | $180.7 million | $140.8 million |
| Operating Margin % | 2.50% | 2.10% |
| Cash from Operating Activities | $62.9 million | $210.3 million |
| Total Assets | $1,776.2 million | $1,528.0 million |
| Long-Term Debt | $359.2 million | $283.8 million |
| Shareholders' Equity | $689.1 million | $614.4 million |
| Days Sales Outstanding (DSO) | 24.5 days | 23.6 days |
| Inventory Turnover | 10.4 | 9.7 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 8.2% to $7.2 billion, driven primarily by greater sales to existing customers (approx. 90% of increase) and the acquisition of The Burrows Company (approx. 10% of increase).
- Profitability: Net income rose 28% to $93.3 million. Operating earnings increased 28% to $180.7 million, aided by improved gross margins and lower interest expense.
- Acquisitions: Acquired The Burrows Company on October 1, 2008, for approximately $17.2 million in cash plus $56.1 million of assumed debt. This contributed roughly 2% to total 2008 revenue.
- Divestitures: Classified its Direct-to-Consumer (DTC) business as discontinued operations in December 2008. The business was sold for $63 million in January 2009. The DTC segment resulted in a loss of $7.9 million in 2008 due to exit costs.
- Cash Flow: Operating cash flow decreased significantly to $62.9 million from $210.3 million in 2007, largely due to increased accounts receivable and inventory levels associated with the Burrows acquisition.
- Debt: Long-term debt increased to $359.2 million, reflecting borrowings used to fund the Burrows acquisition.
Guidance, Outlook, Risks, and Unusual Items
- Management Commentary: Management expects competitive pricing pressures to continue. The company is focusing on margin initiatives through consulting services (OMSolutions) and private label products (MediChoice) to counteract lower product margins.
- Unusual Items:
- Discontinued Operations: A $7.8 million pre-tax charge was recorded in 2008 for costs associated with exiting the DTC business (severance, abandoned software, contract termination).
- Interest Rate Swaps: The company terminated interest rate swaps in 2008 following the bankruptcy of Lehman Brothers (counterparty), realizing a $3.1 million loss included in interest expense.
- Risks and Contingencies:
- Customer Concentration: Approximately 70% of revenue comes from members of three GPOs (Novation, Premier, Broadlane). The top 10 customers represented 20% of revenue.
- Supplier Concentration: The top 10 suppliers accounted for 56% of revenue. Changes in supplier terms or direct-to-hospital sales by suppliers pose a risk.
- Economic Climate: Deterioration in the financial climate could reduce patient demand and compromise customers' ability to pay.
- Regulatory: Subject to extensive federal and state regulations (FDA, HIPAA, Medicare/Medicaid) and potential changes in healthcare reimbursement practices.
Investor Verification Checklist
- Discontinued Operations: Verify the final sale price and closing date of the DTC business (reported as $63 million, closed Jan 2, 2009) and confirm the treatment of exit costs.
- Acquisition Integration: Assess the integration progress and financial contribution of The Burrows Company, which was acquired late in the fiscal year.
- Liquidity Position: Review the $146.7 million remaining availability under the $306 million revolving credit facility and the impact of Lehman Brothers' default on the facility's total capacity.
- Working Capital Trends: Monitor Days Sales Outstanding (DSO) and inventory levels, which increased in 2008, potentially signaling collection or inventory management challenges.
- Supplier Relationships: Evaluate the stability of relationships with top suppliers (e.g., Covidien, Johnson & Johnson) which collectively represent a significant portion of revenue.